Novo Nordisk A/S (NYSE:NVO) Stake Raised by Romano Brothers AND Company

Romano Brothers AND Company raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 12.0% during the 4th quarter, HoldingsChannel reports. The fund owned 6,328 shares of the company’s stock after purchasing an additional 680 shares during the period. Romano Brothers AND Company’s holdings in Novo Nordisk A/S were worth $544,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Strategic Investment Solutions Inc. IL acquired a new stake in Novo Nordisk A/S during the second quarter valued at $25,000. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $28,000. Capital Performance Advisors LLP bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $42,000. Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the third quarter worth approximately $48,000. Finally, M&R Capital Management Inc. raised its position in Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after acquiring an additional 297 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on NVO shares. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, BMO Capital Markets cut their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Trading Down 5.2 %

Shares of NYSE:NVO opened at $78.74 on Monday. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market cap of $353.33 billion, a P/E ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45. The stock’s 50-day moving average is $97.76 and its 200-day moving average is $117.05.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.